Management of relapse after allo-SCT for AML and the role of second transplantation.
Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients (only 2-20% patients receive a second allo-SCT), and efforts to increase the number of patients who may benefit from a second allo-SCT are ongoing. In addition, understanding the varied biological processes that are operative in disease relapse has encouraged the development of novel therapies, and could be beneficial to patients who are currently managed conservatively with supportive care for relapsed disease. Incorporating novel combinations of drugs with immunomodulation, although theoretically attractive, should be tested in the setting of clinical trials. In this review, we discuss the currently available approaches for relapsed AML after allo-SCT.
Savani
B N
BN
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-5505, USA. Bipin.Savani@Vanderbilt.Edu
Mielke
S
S
Reddy
N
N
Goodman
S
S
Jagasia
M
M
Rezvani
K
K
D006801:Humans; D056747:Immunomodulation; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000517:prevention & control*; D012008:Recurrence; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous